Experimental Drug Development Centre (EDDC)

Investigations into an under-explored region of SARS-CoV-2’s spike protein reveals detailed structural insights that can represent valuable drug targets.

A*STAR scientists lay the foundations for a circular economy using worms that turn plastics into fertiliser.

A new smartphone app improves the reliability of on-site rapid COVID-19 colorimetric tests, paving the way for safe gatherings in the post-pandemic world.

From the public sector to innovative startups and industry giants, A*STAR scholars are blazing the trail across Singapore’s research ecosystem.

From music streaming technology to COVID-19 tests, A*STAR Assistant Chief Executive (Enterprise) Sze Wee Tan details how the agency is bringing their innovations out of the lab and into the real world.

Through the years, A*STAR has always stood at the forefront of science and technology and innovation. Here’s how A*STAR came to be and what it has in store in the upcoming decades.

A*STAR’s steady investments in R&D and talent create the ideal conditions for impactful science, says its Chief Executive Officer Frederick Chew.

Contrary to popular belief, a new A*STAR study shows that HIV mutations are far from random, emerging at specific locations at specific rates.

The discovery of a new, highly conserved druggable site on the HIV reverse transcriptase could turn the tide in the wake of growing drug resistance.

A*STAR scientists aim to design better immunotherapies by simulating the binding of antibodies to their targets.